EF-009

· Everfront Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EF-009, covering 2025-02-26 to 2025-02-26. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer [Phase 1, Phase 2]